SecurityUPL / Ultra Petroleum Corp. (903914208)
Chairman, President and CEOWATFORD MICHAEL D
Form 4 Count101
Form 8-K Count84
Form SC 13G/A Count32
Form CORRESP Count23

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ultra Petroleum Corp.


DateFormTitle
2018-05-10 10-Q UPL / Ultra Petroleum Corp. 10-Q (Quarterly Report)
2018-05-10 8-K UPL / Ultra Petroleum Corp. 8-K (Current Report)
2018-04-27 10-K/A UPL / Ultra Petroleum Corp. 10-K/A (Annual Report)
2018-04-20 8-K UPL / Ultra Petroleum Corp. 8-K (Current Report)
2018-03-23 424B3 UPL / Ultra Petroleum Corp. 424B3 (Prospectus)
2018-03-12 POS AM UPL / Ultra Petroleum Corp. POS AM
2018-03-12 8-K UPL / Ultra Petroleum Corp. 8-K (Current Report)
2018-02-28 10-K UPL / Ultra Petroleum Corp. 10-K (Annual Report)
2018-02-15 SC 13G/A UPL / Ultra Petroleum Corp. / Blue Ridge Capital, L.L.C. - ULTRA PETROLEUM CORP. (Passive Investment)
2018-02-15 SC 13G/A UPL / Ultra Petroleum Corp. / Scoggin International Fund, Ltd. - SC 13G/A (Passive Investment)
2018-02-15 SC 13G/A UPL / Ultra Petroleum Corp. / Blue Ridge Capital, L.L.C. - ULTRA PETROLEUM CORP. (Passive Investment)
2018-02-16 SC 13G/A UPL / Ultra Petroleum Corp. / Scoggin International Fund, Ltd. - SC 13G/A (Passive Investment)
2018-02-14 SC 13G/A UPL / Ultra Petroleum Corp. / WHITEBOX ADVISORS LLC - 3G/A (Passive Investment)
2018-02-14 SC 13G/A UPL / Ultra Petroleum Corp. / WHITEBOX ADVISORS LLC - 3G/A (Passive Investment)
2018-02-09 SC 13G UPL / Ultra Petroleum Corp. / VANGUARD GROUP INC - 3G (Passive Investment)
2018-02-09 SC 13G UPL / Ultra Petroleum Corp. / VANGUARD GROUP INC - 3G (Passive Investment)
2018-02-05 SC 13D/A UPL / Ultra Petroleum Corp. / FIR TREE INC. - ULTRA PETROLEUM CORP. (Activist Investment)
2018-02-05 SC 13D/A UPL / Ultra Petroleum Corp. / FIR TREE INC. - ULTRA PETROLEUM CORP. (Activist Investment)
2018-02-01 SC 13G UPL / Ultra Petroleum Corp. / BlackRock Inc. - 3G (Passive Investment)
2018-02-01 SC 13G UPL / Ultra Petroleum Corp. / BlackRock Inc. - 3G (Passive Investment)
2018-01-31 SC 13D/A UPL / Ultra Petroleum Corp. / FIR TREE INC. - ULTRA PETROLEUM CORP. (Activist Investment)
2018-01-31 SC 13D/A UPL / Ultra Petroleum Corp. / FIR TREE INC. - ULTRA PETROLEUM CORP. (Activist Investment)
2018-01-10 SC 13G/A UPL / Ultra Petroleum Corp. / Warlander Asset Management, LP - ULTRA PETROLEUM CORP. (Passive Investment)
2018-01-10 SC 13G/A UPL / Ultra Petroleum Corp. / Warlander Asset Management, LP - ULTRA PETROLEUM CORP. (Passive Investment)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 903914208